Author appearances across the area in July offer such novel approaches to beating the heat as curling up with a chilling thriller or perusing a variety of genres with a
Epsilogen Limited Announces Nature Cites IgE Antibodies as Technology to Watch
Epsilogen is the leading developer of novel IgE antibodies for the treatment of cancer
LONDON, UK / ACCESSWIRE / February 16, 2021
/ Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, notes that IgEs and their potential as a great way for targeting cancer cells for killing
1 were cited in a Technology Feature article in the leading science journal,
Nature. Entitled Seven technologies to watch in 2021
2, the article provided views from seven leading researchers from across the life sciences. Alicia Chenoweth, cancer immunologist at King s College London and co-chair of the 2022 Antibody Biology and Engineering Gordon Research Conference, exemplified IgEs in her section outlining emerging antibody engineering technologies that she believes could have a significant impact on science in the coming year.